Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
- Authors
- Kim, Bum Jun; Jee, Hee-Jung; Rha, Sun Young; Han, Hye Sook; Ryu, Min-Hee; Park, Se Hoon; Kim, Jong Gwang; Bae, Woo Kyun; Lee, Keun-Wook; Oh, Do-Youn; Byun, Ji-Hye; Kim, Dong Sook; Suh, Young Ju; An, Hyonggin; Zang, Dae Young
- Issue Date
- May-2022
- Publisher
- Springer Verlag
- Keywords
- Stomach neoplasms; Ramucirumab; Paclitaxel; ErbB-2
- Citation
- Gastric Cancer, v.25, no.3, pp 609 - 618
- Pages
- 10
- Indexed
- SCIE
SCOPUS
- Journal Title
- Gastric Cancer
- Volume
- 25
- Number
- 3
- Start Page
- 609
- End Page
- 618
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/55286
- DOI
- 10.1007/s10120-021-01276-4
- ISSN
- 1436-3291
1436-3305
- Abstract
- Background
A subgroup analysis of data from a nationwide study (KCSG-ST19-16) was performed to evaluate the efficacy and safety of second-line ramucirumab plus paclitaxel treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
Methods
The KCSG-ST19-16 study enrolled a total of 1063 patients from 56 hospitals in South Korea with advanced gastric or GEJ adenocarcinoma, who had received second-line treatment with ramucirumab plus paclitaxel. HER2 status was known for 994 (93.5%) of these patients, who were thus included in the subgroup analysis.
Results
In total, 163 of 994 patients (16.4%), had HER2-positive gastric or GEJ adenocarcinoma. The objective response rate to ramucirumab plus paclitaxel treatment was significantly higher in patients with HER2-positive disease compared to those with HER2-negative disease (23.0% [95% confidence interval (CI), 15.9–30.1] vs. 15.1% [95% CI, 12.3–17.9], p = 0.025). The median progression-free survival was longer in patients with HER2-positive versus HER2-negative disease, but the difference was not statistically significant (4.3 months [95% CI, 3.7–5.3] vs 3.7 months [95% CI, 3.4–4.0], p = 0.054). There was no statistically significant difference in median overall survival (OS) between the groups (9.8 months [95% CI, 8.9–12.3] vs 10.1 months [95% CI, 9.2–10.9], p = 0.564).
Conclusions
In patients with HER2-positive gastric or GEJ adenocarcinoma, the objective response rate to second-line treatment with ramucirumab plus paclitaxel was significantly higher compared to patients with HER2-negative disease. However, an increased response to treatment was not associated with an improvement in OS.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 1. Basic Science > Department of Biostatistics > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.